Individuals Discontinuing Weight-Loss Injections Gain Back Pounds Far More Rapidly Than People Using Diet and Exercise

New research reveals that individuals who discontinue blockbuster weight-loss injections like Wegovy and Mounjaro may regain reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise regimens.

Research printed in a prominent health publication points out that while obese individuals often shed substantial amounts of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month upon discontinuation.

"People buying such drugs need to be informed of the potential of rapid rebound weight gain when the treatment concludes," warns expert Dr. Susan Jebb.

That rate of regain implies a return to original mass within about one and a half years.

Comparing Treatments

The study, which examined dozens of studies involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with conventional dieting.

Researchers emphasize that individuals who lose weight through diet and exercise generally experience a slower weight regain—around 0.1 kg a month—after stopping.

Explaining the Rapid Rebound

Experts propose the way of the injections explains the accelerated weight return.

GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.

"Long-term administration of the hormone levels several times higher than normal may cause the body to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.

"Stopping of this medication leads to appetite is unsuppressed, making binge eating a significant risk."

A Lifelong Disease?

Medical guidelines recommend the injections for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.

Professionals say that, due to the likelihood of relapse, the treatment is often ongoing.

This view is reinforced by drug manufacturers, who say that the findings "emphasize the long-term nature of obesity," similar to managing diseases like hypertension.

User Testimonies

Individuals who have stopped the medication explain a intense return of appetite.

"I experienced something that goes on and you're instantly extremely hungry," recalled an individual.

This difficulty is worsened if users have not adopted sustainable dietary or behavioural modifications during therapy.

Widespread Interest

Survey data indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.

• Use is greater among females than men.
• The middle-aged demographic shows the highest level of interest.
• A large proportion access the medications through private healthcare rather than the NHS.

Finally, experts stress that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone solution and lasting health benefits hinges on combined lifestyle management.